| Literature DB >> 27294915 |
Kadir Ozaltin1, Marián Lehocký2, Petr Humpolíček3, Jana Pelková4,5, Petr Sáha6.
Abstract
Beside biomaterials' bulk properties, their surface properties are equally important to control interfacial biocompatibility. However, due to the inadequate interaction with tissue, they may cause foreign body reaction. Moreover, surface induced thrombosis can occur when biomaterials are used for blood containing applications. Surface modification of the biomaterials can bring enhanced surface properties in biomedical applications. Sulfated polysaccharide coatings can be used to avoid surface induced thrombosis which may cause vascular occlusion (blocking the blood flow by blood clot), which results in serious health problems. Naturally occurring heparin is one of the sulfated polysaccharides most commonly used as an anticoagulant, but its long term usage causes hemorrhage. Marine sourced sulfated polysaccharide fucoidan is an alternative anticoagulant without the hemorrhage drawback. Heparin and fucoidan immobilization onto a low density polyethylene surface after functionalization by plasma has been studied. Surface energy was demonstrated by water contact angle test and chemical characterizations were carried out by Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy. Surface morphology was monitored by scanning electron microscope and atomic force microscope. Finally, their anticoagulation activity was examined for prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT).Entities:
Keywords: anticoagulant; biomaterials; fucoidan; heparin; plasma treatment; thrombosis
Mesh:
Substances:
Year: 2016 PMID: 27294915 PMCID: PMC4926442 DOI: 10.3390/ijms17060908
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Chemical structure of anticoagulants: (a) Heparin; (b) Fucoidan.
Water contact angle (θw) and average surface roughness (Ra) values.
| Samples | PE | PEH | PEF | PET | PETH | PETF |
|---|---|---|---|---|---|---|
| θw (°) | 85.3 (±3.4) | 81.9 (±12.2) | 79.4 (±8.3) | 56.9 (±11) | 79.6 (±5.3) | 59.1 (±9) |
| 24.2 | 13.9 | 20.3 | 46.7 | 17.9 | 24 |
PE, reference polyethylene samle; PEH, heparin immobilized sample before plasma treatment; PEF, fucoidan immobilized sample before plasma treatment; PET, plasma modified sample; PETH, heparin immobilized sample after plasma treatment; PETF, fucoidan immobilized sample after plasma treatment.
Figure 2Surface morphology by scanning electron microscope (SEM): (a) PE; (b) PET; (c) PEH; (d) PEF; (e) PETH; and (f) PETF.
Figure 3Surface topography by atomic force microscope (AFM): (a) PE; (b) PET; (c) PEH; (d) PEF; (e) PETH; and (f) PETF.
Figure 4Attenuated total reflectance Fourier transform infrared ATR-FTIR spectra.
Elemental compositions and ratios of the tested surfaces obtained by X-Ray photoelectron spectroscopy (XPS).
| Samples | C1s% | O1s% | N1s% | S2p% | O1s/C1s | N1s/C1s | S2p/C1s |
|---|---|---|---|---|---|---|---|
| PE | 98.7 | 1.3 | - | - | 0.013 | - | - |
| PEH | 98.6 | 1.4 | - | - | 0.014 | - | - |
| PEF | 98.7 | 1.3 | - | - | 0.013 | - | - |
| PET | 87.2 | 11.7 | 1.1 | - | 0.134 | 0.013 | - |
| PETH | 85.7 | 13.3 | 0.8 | 0.2 | 0.155 | 0.009 | 0.0023 |
| PETF | 82.3 | 14.8 | 0.5 | 2.4 | 0.18 | 0.006 | 0.0292 |
Antithrombotic test results. PT: Prothrombin time; aPTT: activated partial thromboplastin time; TT: Thrombin time.
| Samples | PT (S) | aPTT (S) | TT (S) |
|---|---|---|---|
| PE (Reference) | 11.5 | 24.8 | 15.9 |
| PEH | 11.5 | 25 | 16.5 |
| PEF | 11.2 | 24.1 | 16.8 |
| PET | 11.4 | 25.9 | 16.8 |
| PETH | 11.5 | 25.7 | 16.6 |
| PETF | 10.9 | 27.3 | 20.9 |
| PETA | 11.5 | 25.2 | 16.3 |
| PETAH | 11.6 | 26.5 | 17.2 |
| PETAF | 11.1 | 26.5 | 18 |
| PETM | 11.7 | 26.4 | 16.9 |
| PETMH | 11.4 | 25.2 | 16.7 |
| PETMF | 11 | 24.2 | 16.5 |
| PETD | 11.4 | 24.2 | 16.6 |
| PETDH | 11.4 | 24.1 | 16.5 |
| PETDF | 11 | 27.1 | 19.5 |
Figure 5The schematic representation of the process. R stands for grafted Allylamine (AAM), N-allylmethylamine (MAAM), and N,N-dimethylallylamine (DAAM) and A stands for anticoagulants of heparin and fucoidan.